Showing 2321-2330 of 3223 results for "".
- Aurion Biotech Receives Approval in Japan for First Allogeneic Cell Therapy to Treat Corneal Endothelial Diseasehttps://modernod.com/news/aurion-biotech-receives-approval-in-japan-for-first-allogeneic-cell-therapy-to-treat-corneal-endothelial-disease/2481486/Aurion Biotech announced it has received regulatory approval from Japan’s Pharmaceuticals and Medical Devices Agency (PMDA) for its novel cell therapy, Vyznova, for the treatment of bullous keratopathy of the cornea. The company believes this is the first regulatory approval in the world fo
- Zeiss Acquires All Shares of Tooz, Maker of Augmented Reality Opticshttps://modernod.com/news/zeiss-acquires-tooz-maker-of-augmented-reality-and-virtual-reality-glasses/2481447/Zeiss announced it has acquired the shares of the joint venture tooz technologies, which was founded together with Deutsche Telekom in 2018 and is developer of high-tech optics in the area of augmented reality. Until now, Zeiss and Deutsche Telekom held 50% of the shares in the sta
- Akorn Files for Chapter 7 Bankruptcy; to Close All US Siteshttps://modernod.com/news/akorn-pharma-to-close-all-us-sites/2481445/Akorn Pharmaceuticals, a maker of generic and branded drugs, announced it is ceasing operations. The company, which offered more than 20 ophthalmic products, has filed for chapter 7 bankruptcy and is shutting down US operations. The news was first
- Cellusion and Minaris Regenerative Medicine Enter Alliance for the Manufacturing of Corneal Endothelial Cell Regenerative Therapyhttps://modernod.com/news/cellusion-and-minaris-regenerative-medicine-enter-alliance-for-the-manufacturing-of-corneal-endothelial-cell-regenerative-therapy/2481170/Cellusion, a Japanese regenerative medicine startup aiming to solve the global corneal transplant waiting list problem, and Minaris Regenerative Medicine, a global contract and development manufacturing organization, announced a Letter of Intent (LOI) of the Manufacturing of CLS001 for a cor
- First Dry Eye Disease Education Initiative Event from World Council of Optometry and Alcon Set for November 8https://modernod.com/news/first-dry-eye-disease-education-initiative-event-from-world-council-of-optometry-and-alcon-set-for-november-8/2481153/The
- Cellusion and Minaris Regenerative Medicine Enter into Business Alliance for the Manufacturing of CLS001 for a Corneal Endothelial Cell Regenerative Therapyhttps://modernod.com/news/cellusion-and-minaris-regenerative-medicine-enter-into-business-alliance-for-the-manufacturing-of-cls001-for-a-corneal-endothelial-cell-regenerative-therapy/2481150/Cellusion, a Japanese regenerative medicine startup aiming to solve the global corneal transplant waiting list problem, and Minaris Regenerative Medicine, a global contract and development manufacturing organization, announced a letter of intent (LOI) of the manufacturing of CLS001 for a cor
- World Council of Optometry and Alcon to Host Dry Eye Disease Education Initiativehttps://modernod.com/news/world-council-of-optometry-and-alcon-to-host-dry-eye-disease-education-initiative/2481088/The
- AbbVie and iSTAR Medical Announce Strategic Alliancehttps://modernod.com/news/abbvie-and-istar-medical-announce-strategic-alliance/2480980/AbbVie and iSTAR Medical announced a strategic transaction to further develop and commercialize iSTAR Medical’s MINIject device, a minimally invasive glaucoma surgical (MIGS) device for patients with glaucoma. The deal gives AbbVie the exclusive right to acquire iST
- Phase 4 PALADIN Study Confirms Positive Predictive Value of Corticosteroid Course Prior to Iluvien Use for IOP Outcomeshttps://modernod.com/news/phase-4-paladin-study-confirms-positive-predictive-value-of-corticosteroid-course-prior-to-iluvien-use-for-iop-outcomes/2480855/Alimera Sciences announced that the phase 4 PALADIN study confirmed the benefit of using a prior course of corticosteroid as indicated in the Iluvien U.S. label to mitigate the risk of uncontrolled IOP elevation. These results were presented at the annual Association for Researc
- Centricity Vision Announces New Technologies Under Development, Zeptolink and 5.5 mm Capsulotomy; Names Leonard Borrmann to Lead R&Dhttps://modernod.com/news/centricity-vision-announces-new-technologies-under-development-zeptolink-and-55-mm-capsulotomy-names-leonard-borrmann-to-lead-rd/2480783/Centricity Vision announced two product innovations under development, the Zeptolink platform and Zepto 5.5 mm capsulotomy technology. The company has also appointed Leonard Borrmann, PharmD, to lead research and development. "The Zepto technology is elevating the precisi